98%
921
2 minutes
20
Background: Premedication regimens to prevent infusion-related reactions typically include steroids and first-generation antihistamines, primarily diphenhydramine. With the recent approval of intravenous cetirizine, a second-generation antihistamine, for acute urticaria and angioedema, reevaluating premedication standard regimens is warranted. This review explores whether cetirizine can improve efficiency and reduce side effects in outpatient infusion settings.
Methods: A literature review was conducted using the PICO question: "In adult and pediatric outpatient infusion patients receiving premedication, how does intravenous (IV) cetirizine compare to IV diphenhydramine in preventing infusion-related and adverse drug reactions?" The authors searched in CINAHL, EBSCOhost, and PubMed for English-language articles from 2019 to 2025, reflecting the time since intravenous cetirizine's FDA approval. Keywords included diphenhydramine, cetirizine, infusion-related reactions, and premedication. Thirty-five articles were identified; after removing duplicates and excluding those using only oral cetirizine or focused solely on acute urticaria, 8 studies were selected for full review.
Results: Intravenous cetirizine was found to be a safe, effective alternative to IV diphenhydramine, with similar efficacy in preventing reactions. It was associated with fewer adverse effects, less sedation, and reduced patient chair time, potentially improving both workflow efficiency and patient satisfaction.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/NAN.0000000000000614 | DOI Listing |
J Infus Nurs
September 2025
Author Affiliation: BonSecours, Mercy Health, Hanover Outpatient Infusion Center, Mechanicsville, VA (Liverman); BonSecours, Mercy Health, Bremo Outpatient Infusion Center North Richmond, VA (Newman and Smith).
Background: Premedication regimens to prevent infusion-related reactions typically include steroids and first-generation antihistamines, primarily diphenhydramine. With the recent approval of intravenous cetirizine, a second-generation antihistamine, for acute urticaria and angioedema, reevaluating premedication standard regimens is warranted. This review explores whether cetirizine can improve efficiency and reduce side effects in outpatient infusion settings.
View Article and Find Full Text PDFMult Scler J Exp Transl Clin
August 2025
Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
Background: Multiple sclerosis (MS), a chronic neurological disease, is typically managed with disease-modifying therapies (DMTs) to reduce relapse rates and slow disease progression. Some of these DMTs can cause infusion-related reactions (INRRs), which range from mild symptoms to severe allergic reactions. Corticosteroids are commonly used in premedication regimens to mitigate INRRs.
View Article and Find Full Text PDFAnn Hematol
July 2025
Division of Hematology, Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden.
Rituximab is a monoclonal antibody used in the treatment of B-cell malignancies. Infusion reactions are common during the first exposure but decrease with subsequent infusions. We here present our experience with a protocol for a 30-minute intravenous infusion of rituximab (SpeedR) to patients who have previously tolerated a 90-minute rituximab infusion.
View Article and Find Full Text PDFMedicine (Baltimore)
July 2025
Department of Rheumatology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong Province, China.
Rationale: Castleman disease (CD) is a rare lymphoproliferative disorder characterized by nonmalignant lymph node enlargement, often associated with systemic symptoms. It is classified into unicentric disease (involving a single enlarged lymph node) and multicentric disease (affecting multiple lymph node stations). In some cases of idiopathic multicentric Castleman disease (iMCD), elevated levels of various serum inflammatory markers are observed, and histologically, the lymph node enlargement resembles that caused by autoimmune diseases, making diagnosis challenging.
View Article and Find Full Text PDFFront Immunol
March 2025
Department of Pharmacy, Sichuan Provincial Women's and Children's Hospital/The Affiliated Women's and Children's Hospital of Chengdu Medical College, Chengdu, China.
Background: Drug-induced immune hemolytic anemia (DIIHA) is a rare but serious disease associated with various antibiotics, which is often misdiagnosed. DIIHA often leads to adverse outcomes, including organ failure and even death. Ceftriaxone is one of the most common drugs that cause DIIHA.
View Article and Find Full Text PDF